InsiderClue
Insiders · Profile

Gline Matthew

CEO at Roivant Sciences. Filing since 7 Mar 2022. CIK 0001750094

Company
Date
Role
Action
Shares
Amount
Of holding
ROIV Roivant Sciences Ltd.
16 Apr 2026
CEO
Sold at will
289,774
$8.45M
1.7%
ROIV Roivant Sciences Ltd.
15 Dec 2025
CEO
Sold at will
1,740,000
$37.72M
9.1%
ROIV Roivant Sciences Ltd.
18 Sep 2025
CEO
Bought
3,315
$49.96K
0.0%
ROIV Roivant Sciences Ltd.
23 Sep 2024
CEO
Sold on a plan
1,983,257
$23.38M
10.0%
ROIV Roivant Sciences Ltd.
25 Oct 2022
CEO
Sold, plan not stated
19,276
$84.81K
1.6%
ROIV Roivant Sciences Ltd.
23 Sep 2022
CEO
Sold, plan not stated
21,053
$64.63K
1.7%
ROIV Roivant Sciences Ltd.
24 Aug 2022
CEO
Sold, plan not stated
20,009
$74.23K
1.6%
ROIV Roivant Sciences Ltd.
25 Jul 2022
CEO
Sold, plan not stated
20,455
$88.57K
1.6%
ROIV Roivant Sciences Ltd.
23 Jun 2022
CEO
Sold, plan not stated
19,855
$86.17K
1.6%
ROIV Roivant Sciences Ltd.
20 May 2022
CEO
Sold, plan not stated
139,791
$517.23K
10.0%
ROIV Roivant Sciences Ltd.
25 Apr 2022
CEO
Sold, plan not stated
8,509
$32.67K
0.6%
ROIV Roivant Sciences Ltd.
30 Mar 2022
CEO
Sold, plan not stated
33,686
$163.04K
2.3%
ROIV Roivant Sciences Ltd.
25 Mar 2022
CEO
Sold, plan not stated
35,386
$179.05K
2.3%
ROIV Roivant Sciences Ltd.
18 Mar 2022
CEO
Sold, plan not stated
82,006
$420.69K
5.2%
ROIV Roivant Sciences Ltd.
7 Mar 2022
CEO
Sold, plan not stated
92,324
$509.63K
5.5%
15 decisions on file.